Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Plasma 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer in whites: a nested case–control study in the multiethnic cohort study

Authors: Yeonju Kim, Adrian A Franke, Yurii B Shvetsov, Lynne R Wilkens, Robert V Cooney, Galina Lurie, Gertraud Maskarinec, Brenda Y Hernandez, Loïc Le Marchand, Brian E Henderson, Laurence N Kolonel, Marc T Goodman

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Higher sunlight exposure is correlated with lower incidence of breast cancer in ecological studies, but findings from prospective studies regarding the association of circulating levels of vitamin D with the risk of breast cancer have been null. The objective of this study was to examine the relation between plasma levels of vitamin D and the risk of postmenopausal breast cancer.

Methods

We conducted a nested case–control study within the Multiethnic Cohort Study of five race/ethnic groups (white, African-American, Native Hawaiian, Japanese, and Latino) from Hawaii and Los Angeles between 2001 and 2006. Pre-diagnostic plasma levels of 25-hydroxyvitamin D2 [25(OH)D2], 25-hydroxyvitamin D3 [25(OH)D3] and 25(OH)D (sum of 25(OH)D2 and 25(OH)D3) were examined among 707 postmenopausal breast cancer cases and matched controls.

Results

Using conditional logistic regression models, 20 ng/mL increases of plasma 25(OH)D3 (odds ratio (OR) 0.28; 95% confidence interval (CI) 0.14-0.56) and 25(OH)D (OR 0.43; 95% CI 0.23-0.80) were inversely associated with breast cancer risk among white women, but not among women in other race/ethnic groups. Using two-segmented, piecewise-linear logistic regression models, the change-points of the ORs, either for 25(OH)D3 or for 25(OH)D, were detected as 20 ng/mL among whites.

Conclusions

Circulating 25(OH)D3 and 25(OH)D were associated with a reduced risk of postmenopausal breast cancer among whites, but not in other ethnic groups, who reside in low latitude regions.
Literature
1.
Boscoe FP, Schymura MJ: Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993–2002. BMC Cancer. 2006, 6: 264-10.1186/1471-2407-6-264.CrossRefPubMedPubMedCentral
2.
Gorham ED, Garland FC, Garland CF: Sunlight and breast cancer incidence in the USSR. Int J Epidemiol. 1990, 19 (4): 820-824. 10.1093/ije/19.4.820.CrossRefPubMed
3.
Grant WB: An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer. 2002, 94 (6): 1867-1875. 10.1002/cncr.10427.CrossRefPubMed
4.
IARC: Vitamin D and cancer. IARC Working group reports vol.5. 2008, Lyon: International Agency for research on Cancer, 5:
5.
Gissel T, Rejnmark L, Mosekilde L, Vestergaard P: Intake of vitamin D and risk of breast cancer—a meta-analysis. J Steroid Biochem Mol Biol. 2008, 111 (3–5): 195-199.CrossRefPubMed
6.
Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M, Newmark H, Holick MF, Garland FC: Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol. 2007, 103 (3–5): 708-711.CrossRefPubMed
7.
Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P: Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 2011, 128 (6): 1414-1424. 10.1002/ijc.25439.CrossRefPubMed
8.
Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H: Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer. 2010, 46 (12): 2196-2205. 10.1016/j.ejca.2010.03.037.CrossRefPubMed
9.
Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J: Serum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case–control study. Int J Cancer. 2010, 127 (9): 2159-2168. 10.1002/ijc.25215.CrossRefPubMed
10.
Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE: Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Bioiomarkers Prev. 2005, 14 (8): 1991-1997. 10.1158/1055-9965.EPI-04-0722.CrossRef
11.
Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE: Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II. Breast Cancer Res. 2011, 13 (3): R50-10.1186/bcr2880.CrossRefPubMedPubMedCentral
12.
Engel P, Fagherazzi G, Boutten A, Dupre T, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F: Serum 25(OH) vitamin D and risk of breast cancer: a nested case–control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev. 2010, 19 (9): 2341-2350. 10.1158/1055-9965.EPI-10-0264.CrossRefPubMed
13.
Freedman DM, Chang S-C, Falk RT, Purdue MP, Huang W-Y, McCarty CA, Hollis BW, Graubard BI, Berg CD, Ziegler RG: Serum levels of Vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2008, 17 (4): 889-894. 10.1158/1055-9965.EPI-07-2594.CrossRefPubMedPubMedCentral
14.
McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, Gapstur SM, Thun MJ, Calle EE: Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res. 2009, 11 (4): R64-10.1186/bcr2356.CrossRefPubMedPubMedCentral
15.
Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L, Mosekilde L: Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case–control study. Cancer Epidemiol Biomarkers Prev. 2009, 18 (10): 2655-2660. 10.1158/1055-9965.EPI-09-0531.CrossRefPubMed
16.
Scarmo S, Afanasyeva Y, Lenner P, Koenig K, Horst R, Clendenen T, Arslan A, Chen Y, Hallmans G, Lundin E, et al: Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case–control study. Breast Cancer Res. 2013, 15 (1): R15-10.1186/bcr3390.CrossRefPubMedPubMedCentral
17.
Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O’Sullivan MJ, Yasmeen S, et al: Calcium plus Vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008, 100 (22): 1581-1591. 10.1093/jnci/djn360.CrossRefPubMedPubMedCentral
18.
Neuhouser ML, Manson JE, Millen A, Pettinger M, Margolis K, Jacobs ET, Shikany JM, Vitolins M, Adams-Campbell L, Liu S, et al: The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol. 2012, 175 (7): 673-684. 10.1093/aje/kwr350.CrossRefPubMedPubMedCentral
19.
Ford L, Graham V, Wall A, Berg J: Vitamin D concentrations in an UK inner-city multicultural outpatient population. Ann Clin Biochem. 2006, 43 (Pt 6): 468-473.CrossRefPubMed
20.
Holick M: Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr. 1995, 61 (3): 638S-645S.PubMed
21.
Nessvi S, Johansson L, Jopson J, Stewart A, Reeder A, McKenzie R, Scragg RK: Association of 25-hydroxyvitamin D3)levels in adult New Zealanders with ethnicity, skin color and self-reported skin sensitivity to sun exposure. Photochem Photobiol. 2011, 87 (5): 1173-1178. 10.1111/j.1751-1097.2011.00956.x.CrossRefPubMed
22.
Ashwell M, Stone EM, Stolte H, Cashman KD, Macdonald H, Lanham-New S, Hiom S, Webb A, Fraser D: UK Food Standards Agency Workshop Report: an investigation of the relative contributions of diet and sunlight to vitamin D status. Br J Nutr. 2010, 104 (4): 603-611. 10.1017/S0007114510002138.CrossRefPubMed
23.
Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA: Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. Am J Clin Nutr. 2008, 88 (6): 1519-1527. 10.3945/ajcn.2008.26182.CrossRefPubMedPubMedCentral
24.
IOM (Institue of Medicine): Dietary reference intakes for calcium and vitamin D. 2011, Washington, D.C: The National Academy Press
25.
Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, et al: IOM Committee Members Respond to Endocrine Society Vitamin D Guideline. J Clin Endocrinol Metab. 2012, 97 (4): 1146-1152. 10.1210/jc.2011-2218.CrossRefPubMed
26.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM: Evaluation, treatment, and prevention of Vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011, 96 (7): 1911-1930. 10.1210/jc.2011-0385.CrossRefPubMed
27.
Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, Stram DO, Monroe KR, Earle ME, Nagamine FS: A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol. 2000, 151 (4): 346-357. 10.1093/oxfordjournals.aje.a010213.CrossRefPubMedPubMedCentral
28.
Pastor R, Guallar E: Use of two-segmented logistic regression to estimate change-points in epidemiologic studies. Am J Epidemiol. 1998, 148 (7): 631-642. 10.1093/aje/148.7.631.CrossRefPubMed
29.
Manson JE, Mayne ST, Clinton SK: Vitamin D and prevention of cancer–ready for prime time?. N Engl J Med. 2011, 364 (15): 1385-1387. 10.1056/NEJMp1102022.CrossRefPubMed
30.
Nicholas J: Vitamin D and cancer: uncertainty persists; research continues. J Natl Cancer Inst. 2011, 103 (11): 851-852. 10.1093/jnci/djr215.CrossRefPubMed
31.
Zerwekh JE: Blood biomarkers of vitamin D status. Am J Clin Nutr. 2008, 87 (4): 1087S-1091S.PubMed
32.
Engel P, Fagherazzi G, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F: Joint effects of dietary vitamin D and sun exposure on breast cancer risk: results from the French E3N cohort. Cancer Epidemiol Biomarkers Prev. 2011, 20 (1): 187-198. 10.1158/1055-9965.EPI-10-1039.CrossRefPubMed
33.
John EM, Schwartz GG, Dreon DM, Koo J: Vitamin D and breast cancer risk: The NHANES I epidemiologic follow-up study, 1971–1975 to 1992. Cancer Epidemiol Biomarkers Prev. 1999, 8 (5): 399-406.PubMed
34.
Bolland MJ, Grey A, Gamble GD, Reid IR: Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am J Clin Nutr. 2011, 94 (4): 1144-1149. 10.3945/ajcn.111.015032.CrossRefPubMedPubMedCentral
35.
Chai W, Maskarinec G, Cooney RV: Serum 25-hydroxyvitamin D levels and mammographic density among premenopausal women in a multiethnic population. Eur J Clin Nutr. 2010, 64 (6): 652-654. 10.1038/ejcn.2010.36.CrossRefPubMedPubMedCentral
36.
Kuroda T, Shiraki M, Tanaka S, Ohta H: Contributions of 25-hydroxyvitamin D, co-morbidities and bone mass to mortality in Japanese postmenopausal women. Bone. 2009, 44 (1): 168-172. 10.1016/j.bone.2008.03.023.CrossRefPubMed
37.
Millen AE, Wactawski-Wende J, Pettinger M, Melamed ML, Tylavsky FA, Liu S, Robbins J, LaCroix AZ, LeBoff MS, Jackson RD: Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women's Health Initiative Calcium plus Vitamin D clinical trial. Am J Clin Nutr. 2010, 91 (5): 1324-1335. 10.3945/ajcn.2009.28908.CrossRefPubMedPubMedCentral
38.
Ohta H, Kuroda T, Onoe Y, Orito S, Ohara M, Kume M, Harada A, Tsugawa N, Okano T, Sasaki S: The impact of lifestyle factors on serum 25-hydroxyvitamin D levels: a cross-sectional study in Japanese women aged 19–25 years. J Bone Miner Metab. 2009, 27 (6): 682-688. 10.1007/s00774-009-0095-1.CrossRefPubMed
39.
Anderson LN, Cotterchio M, Cole DE, Knight JA: Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev. 2011, 20 (8): 1708-1717. 10.1158/1055-9965.EPI-11-0300.CrossRefPubMed
40.
Ingles SA, Garcia DG, Wang W, Nieters A, Henderson BE, Kolonel LN, Haile RW, Coetzee GA: Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control. 2000, 11 (1): 25-30. 10.1023/A:1008979417618.CrossRefPubMed
41.
McKay JD, McCullough ML, Ziegler RG, Kraft P, Saltzman BS, Riboli E, Barricarte A, Berg CD, Bergland G, Bingham S, et al: Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009, 18 (1): 297-305. 10.1158/1055-9965.EPI-08-0539.CrossRefPubMed
42.
Rollison DE, Cole AL, Tung KH, Slattery ML, Baumgartner KB, Byers T, Wolff RK, Giuliano AR: Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S. Breast Cancer Res Treat. 2011, 132 (2): 683-691.CrossRefPubMedPubMedCentral
43.
Trabert B, Malone KE, Daling JR, Doody DR, Bernstein L, Ursin G, Marchbanks PA, Strom BL, Humphrey MC, Ostrander EA: Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case–control study of Caucasian and African-American women. Breast Cancer Res. 2007, 9 (6): R84-10.1186/bcr1833.CrossRefPubMedPubMedCentral
44.
Khan QJ, Kimler BF, Fabian CJ: The relationship between vitamin D and breast cancer incidence and natural history. Curr Oncol Rep. 2010, 12 (2): 136-142. 10.1007/s11912-010-0081-8.CrossRefPubMed
45.
John EM, Schwartz GG, Koo J, Wang W, Ingles SA: Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J Epidemiol. 2007, 166 (12): 1409-1419. 10.1093/aje/kwm259.CrossRefPubMed
46.
Li B, Byrjalsen I, Glendenning P, Henriksen DB, Hoeck HC, Taranto M, Vasikaran S, Fraser WD, Christiansen C, Qvist P: Selective monitoring of vitamin D2 and D3 supplementation with a highly specific 25-hydroxyvitamin D3 immunoassay with negligible cross-reactivity to 25-hydroxyvitamin D2. Clin Chim Acta. 2009, 404 (2): 144-148. 10.1016/j.cca.2009.03.043.CrossRefPubMed
47.
Heaney RP, Recker RR, Grote J, Horst RL, Armas LA: Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab. 2011, 96 (3): E447-452. 10.1210/jc.2010-2230.CrossRefPubMed
48.
Houghton LA, Vieth R: The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr. 2006, 84 (4): 694-697.PubMed
49.
Metadata
Title
Plasma 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer in whites: a nested case–control study in the multiethnic cohort study
Authors
Yeonju Kim
Adrian A Franke
Yurii B Shvetsov
Lynne R Wilkens
Robert V Cooney
Galina Lurie
Gertraud Maskarinec
Brenda Y Hernandez
Loïc Le Marchand
Brian E Henderson
Laurence N Kolonel
Marc T Goodman
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-29

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses

Research article

A population-based study of breast cancer prevalence in Australia: predicting the future health care needs of women living with breast cancer

Research article

Role of malignant ascites on human mesothelial cells and their gene expression profiles

Research article

Knowledge, awareness and attitudes about cervical cancer among women attending or not an HIV treatment center in Lao PDR

Case report

Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland

Research article

Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits